How would you treat an MMR-proficient T2 N0 low-rectal cancer (measuring 2 cm extending 4-6 cm from the anal verge) in a patient who wishes to preserve his sphincter?
Is there data on neoadjuvant chemo-RT or chemo in this setting?
Answer from: Medical Oncologist at Community Practice
Thanks for the question. I think a multidisciplinary approach is key here. First, I would make sure there is an MRI rectal performed confirming the stage of cancer and also clarify whether the patient would like to have organ preservation approach (not only the sphincter but also the rectum itself)....
Comments
Medical Oncologist at Bhanu Vakkalanka, MD, MBBS Dr. @Sahin, greatly appreciate the answer! NCCN al...
Medical Oncologist at University of Pittsburgh School of Medicine Thank you and I agree these are all valid points!&...
Medical Oncologist at Bhanu Vakkalanka, MD, MBBS It certainly helps. Thank you!
Medical Oncologist at Houston Cancer Treatment and Immunotherapy Center Agree with Dr. @Sahin
Answer from: Radiation Oncologist at Academic Institution
OPERA trial is relevant here, focused on T2-3N0-1 rectal cancers: Gerard et al., PMID 36801007.If you can find a regional Rad Onc to do rectal brachytherapy, that would maximize chances of organ preservation, but even with EBRT boost, organ preservation at 3-years is 68%, better than OPRA, understan...
Dr. @Sahin, greatly appreciate the answer! NCCN al...
Thank you and I agree these are all valid points!&...
It certainly helps. Thank you!
Agree with Dr. @Sahin